Sept 22 (Reuters) – Merck & Co Inc: * U.S. FDA APPROVES UPDATE TO THE LABEL FOR WINREVAIR™ (SOTATERCEPT-CSRK) TO INCLUDE DATA FROM THE PHASE 3 HYPERION TRIAL EVALUATING ADULTS RECENTLY DIAGNOSED WITH
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
(Updates prices) * More rate hikes likely needed, says Fed's Musalem * US-Iran talks in…
Sept 22 (Reuters) - Filana Therapeutics, Inc.: * FILANA THERAPEUTICS ANNOUNCES FDA LIFT OF CLINICAL…
BERLIN, Sept 22 (Reuters) - BMW CEO Milan Nedeljkovic backs voluntary pricing agreements rather than…
By Shashwat Chauhan Sept 22 (Reuters) - Wall Street has turned bullish on Meta Platforms,…
(Adds detail and comment) Sept 22 (Reuters) - Saudi Arabian crude oil exports in July…
(Adds settlement details, earlier probe, attempts to obtain paragraphs 3-8) By Jonathan Stempel NEW YORK,…